Characterizing CaeA-mediated rifampin tolerance in MTB
表征 MTB 中 CaeA 介导的利福平耐受性
基本信息
- 批准号:10595814
- 负责人:
- 金额:$ 25.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-11-10 至 2024-10-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAnimal ModelAntibiotic susceptibilityAntibioticsBiologicalBiological AssayC3HeB/FeJ MouseCandidate Disease GeneCause of DeathCell WallChronicCo-ImmunoprecipitationsCollaborationsCombined Modality TherapyComplementComputer ModelsDNA-Directed RNA PolymeraseDoseDrug EffluxDrug TargetingDrug resistance in tuberculosisEthambutolExhibitsExposure toGenesGenetic ScreeningHomidium BromideHumanInfectionInvestigationKineticsKnock-outKnowledgeLesionLibrariesLipidsLungMass Spectrum AnalysisMeasuresMediatingMedicalMetabolicMetabolic PathwayMicrobiologyModernizationMolecularMorbidity - disease rateMusMutagenesisMycobacterium tuberculosisNecrosisNitroimidazolesNutrientPathogenesisPathway interactionsPenetrationPeptide HydrolasesPermeabilityPharmaceutical PreparationsPhenotypePhysiologicalPopulationPredispositionProcessPropertyProteinsProteolysisPulmonary PathologyRecombinantsRegimenRegulatory PathwayRelapseReportingResearchResearch PersonnelResistanceReverse Transcriptase Polymerase Chain ReactionRifampinSerine ProteaseStreptomycinStressSystems BiologyTestingTimeTuberculosisVirulenceVirulence Factorsantibiotic tolerancebactericidecarboxylesteraseclinical practiceclinically relevantdesigndrug developmentefflux pumpglobal health emergencyin vivointerestlipidomicsmetabolomicsmortalitymouse modelmultidisciplinarymutantmycobacterialnew therapeutic targetnovelpersistent bacterial infectionpre-clinicalprogramspulmonary granulomarelapse preventionsuccesstranscriptomicstransmission processtuberculosis drugstuberculosis treatment
项目摘要
ABSTRACT
Tuberculosis (TB) is one of the top ten causes of death worldwide. Only two new classes of TB drugs
(diarylquinolines and nitroimidazoles) have been introduced into clinical practice since the introduction of the
current multidrug regimen in the 1970s. The lack of success in identifying novel drug targets suggests that the
reinvestigation of mechanisms of action and resistance of currently available drugs may be a more fruitful
approach. Rifampin, which targets the mycobacterial RNA polymerase, is one of the key sterilizing drugs
permitting the modern “short-course” 6-month regimen. The lengthy duration of TB treatment required to prevent
relapse reflects the ability of Mycobacterium tuberculosis (Mtb) to persist in the host in an altered physiological
state characterized by reversible tolerance to first-line anti-tubercular drugs. Several mechanisms have been
reported to contribute to Mtb antibiotic tolerance, including the induction of drug efflux pumps and reduced
penetration of drugs into necrotic tuberculous lesions and across the waxy mycobacterial cell wall. Currently,
there is significant interest in maximizing exposures to rifampin in order to eliminate Mtb “persisters”, however
the mechanisms of tolerance to rifampin and other anti-tubercular drugs remain largely undefined. In order to
address this significant knowledge gap, we conducted a high-throughput transposon (Tn) mutant screen to
identify Mtb genes required for tolerance to rifampin in nutrient-rich broth and in physiologically relevant stress
conditions. Mutants containing a Tn insertion in the rv2224c/caeA gene were 294-fold more susceptible to
rifampin than was wild-type Mtb. This differential antibiotic susceptibility phenotype was confirmed using a
targeted caeA deletion mutant (ΔcaeA) and its complemented strain. We also found that caeA deficiency is
associated with increased rifampin accumulation and increased permeability to the polar molecule ethidium
bromide in Mtb. Previous studies have shown that CaeA, a cell wall-associated carboxylesterase and serine
protease, is critical for Mtb virulence. Disruption of caeA led to prolonged survival of infected mice and highly
reduced lung pathology. Further supporting the potential utility of targeting CaeA in TB treatment, deficiency of
this protein has been associated with increased Mtb susceptibility to the first-line drug ethambutol and the
second-line drug streptomycin. Using a combination of targeted and unbiased approaches, the current proposal
will test the hypothesis that CaeA mediates Mtb tolerance to rifampin by modifying Mtb cell wall composition,
thereby reducing drug permeability. In proof-of-concept studies using a recently generated inducible CaeA
degradation strain, we also will evaluate the treatment-shortening potential of targeting CaeA as adjunctive TB
therapy in a clinically relevant animal model. Our findings are expected to have far-reaching implications for
understanding antibiotic tolerance in Mtb and other persistent bacterial infections.
抽象的
结核病(TB)是全球十大死亡原因之一。只有两类新的结核病药物。
(二芳基喹啉和硝基咪唑)自引入以来已被引入临床实践
目前 20 世纪 70 年代的多药治疗方案在确定新药物靶标方面缺乏成功,这表明
重新研究现有药物的作用机制和耐药性可能会更有成效
利福平以分枝杆菌RNA聚合酶为靶点,是关键的灭菌药物之一。
允许现代“短期”6 个月治疗方案 预防结核病所需的长期治疗。
复发反映了结核分枝杆菌(Mtb)以改变的生理状态在宿主体内持续存在的能力。
这种状态的特征是对一线抗结核药物的可逆耐受。
据报道有助于 Mtb 抗生素耐受,包括诱导药物流出泵并减少
目前,药物渗透到坏死的结核病灶并穿过蜡质分枝杆菌细胞壁。
然而,为了消除结核分枝杆菌“持续存在”,人们对最大限度地增加利福平的暴露量非常感兴趣
对利福平和其他抗结核药物的耐受机制在很大程度上仍不明确。
为了解决这一重大知识差距,我们进行了高通量转座子 (Tn) 突变体筛选
鉴定在营养丰富的肉汤和生理相关应激中对利福平耐受所需的 Mtb 基因
rv2224c/caeA 基因中含有 Tn 插入的突变体对这种情况的敏感性提高了 294 倍。
使用利福平与野生型结核分枝杆菌相比,这种差异的抗生素敏感性表型得到了证实。
靶向caeA缺失突变体(ΔcaeA)及其互补菌株我们还发现caeA缺陷。
与利福平累积增加和极性分子乙锭渗透性增加相关
先前的研究表明,Mtb 中的溴化物是 CaeA,一种细胞壁相关的羧酸酯酶和丝氨酸。
蛋白酶对 Mtb 毒力至关重要,破坏 caeA 可以延长受感染小鼠的存活时间并提高其存活率。
进一步支持靶向 CaeA 在结核病治疗中的潜在效用。
该蛋白与 Mtb 对一线药物乙胺丁醇和
二线药物链霉素,目前的建议是结合有针对性和公正的方法。
将检验 CaeA 通过改变 Mtb 细胞壁组成来介导 Mtb 对利福平的耐受性的假设,
在使用最近产生的诱导型 CaeA 的概念验证研究中。
降解菌株,我们还将评估以 CaeA 作为辅助结核病治疗缩短治疗的潜力
我们的研究结果预计将对临床相关的动物模型产生深远的影响。
了解结核分枝杆菌和其他持续性细菌感染的抗生素耐受性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Petros C Karakousis其他文献
Petros C Karakousis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Petros C Karakousis', 18)}}的其他基金
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters
治疗性疫苗接种可增强对 MTB 持续者的严格反应特异性 T 细胞免疫
- 批准号:
10569001 - 财政年份:2020
- 资助金额:
$ 25.33万 - 项目类别:
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters
治疗性疫苗接种可增强对 MTB 持续者的严格反应特异性 T 细胞免疫
- 批准号:
10341182 - 财政年份:2020
- 资助金额:
$ 25.33万 - 项目类别:
Mentoring in Immunometabolic Dysregulation in TB and TB/HIV
结核病和结核病/艾滋病毒免疫代谢失调的指导
- 批准号:
9975724 - 财政年份:2019
- 资助金额:
$ 25.33万 - 项目类别:
Mentoring in Immunometabolic Dysregulation in TB and TB/HIV
结核病和结核病/艾滋病毒免疫代谢失调的指导
- 批准号:
10190807 - 财政年份:2019
- 资助金额:
$ 25.33万 - 项目类别:
Mentoring in Immunometabolic Dysregulation in TB and TB/HIV
结核病和结核病/艾滋病毒免疫代谢失调的指导
- 批准号:
10429990 - 财政年份:2019
- 资助金额:
$ 25.33万 - 项目类别:
A novel "shock and kill" strategy for eliminating Mtb persisters in the CD4 T-cell-deficient host
一种新的“电击杀灭”策略,用于消除 CD4 T 细胞缺陷宿主中的 Mtb 持续存在
- 批准号:
9208740 - 财政年份:2016
- 资助金额:
$ 25.33万 - 项目类别:
Statins as Adjunctive, Host-Directed Therapy for TB
他汀类药物作为结核病的辅助、宿主导向疗法
- 批准号:
9522566 - 财政年份:2015
- 资助金额:
$ 25.33万 - 项目类别:
相似国自然基金
基于前景理论的ADHD用药决策过程与用药依从性内在机制研究
- 批准号:72304279
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于强化学习AI聊天机器人对MSM开展PrEP服药依从性精准干预模式探索及干预效果研究
- 批准号:82373638
- 批准年份:2023
- 资助金额:59 万元
- 项目类别:面上项目
基于HAPA理论的PCI术后患者运动依从性驱动机制与干预方案构建研究
- 批准号:72304180
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于保护动机理论的新确诊青少年HIV感染者抗病毒治疗依从性“游戏+”健康教育及作用机制研究
- 批准号:82304256
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于健康行为程式模型提升高血压患者药物依从性的干预策略构建研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
An Integrated Catheter Dressing for Early Detection of Catheter-related Bloodstream Infections
用于早期检测导管相关血流感染的集成导管敷料
- 批准号:
10647072 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease
结构工程呋喃脂肪酸用于治疗血脂异常和心血管疾病
- 批准号:
10603408 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
Metformin IN Asthma for overweight and obese individuals (MINA)
二甲双胍用于超重和肥胖人群的哮喘治疗 (MINA)
- 批准号:
10740950 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
Investigation of non-canonical opioid signaling in the prefrontal cortex of alcohol-dependent rats
酒精依赖大鼠前额叶皮层非典型阿片类药物信号传导的研究
- 批准号:
10811444 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
Novel application of pharmaceutical AMD3100 to reduce risk in opioid use disorder: investigations of a causal relationship between CXCR4 expression and addiction vulnerability
药物 AMD3100 降低阿片类药物使用障碍风险的新应用:CXCR4 表达与成瘾脆弱性之间因果关系的研究
- 批准号:
10678062 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别: